Natural Management

Understanding AMD — Dry, Wet, and What Changes the Trajectory

AMD comes in two forms. Dry AMD (also called atrophic AMD) accounts for around 85–90% of cases and develops gradually as drusen — yellow deposits of cellular waste — accumulate under the retina, eventually causing the retinal pigment epithelium (RPE) cells to thin and die. In advanced dry AMD, geographic atrophy leaves blind patches in central vision. Wet AMD (neovascular AMD) is less common but more aggressive: abnormal blood vessels grow beneath the retina and leak fluid or blood, causing rapid vision distortion. Most people with wet AMD start with dry AMD.

The disease begins long before symptoms appear. Oxidative stress, chronic low-grade inflammation, impaired complement system regulation, and compromised mitochondrial function in the RPE gradually damage the photoreceptor environment. This means the window for natural intervention is wide — and the evidence supports acting before symptoms develop rather than after.

Lutein, Zeaxanthin, and the Macular Pigment

The macula concentrates two specific carotenoids — lutein and zeaxanthin — in a yellow pigment layer that acts as an internal filter against blue light wavelengths most damaging to photoreceptors. People with higher macular pigment optical density (MPOD) have significantly lower rates of AMD progression. The body cannot synthesise these compounds; they must come from diet or supplementation.

Dietary sources include:

• Kale, spinach, collard greens, Swiss chard — by far the richest sources (kale: ~18–39 mg per 100g combined)
• Egg yolks — lower in absolute quantity but highly bioavailable due to fat content
• Peas, corn, peppers — moderate sources
• Broccoli, Brussels sprouts — good secondary sources

The AREDS2 trial supplemented with 10 mg lutein + 2 mg zeaxanthin daily — these are the doses used if supplementing rather than relying solely on diet. At 5 years, the primary endpoint showed a non-significant trend toward benefit; however, secondary analyses showed that people in the lowest dietary quintile for these carotenoids had a 26% reduced risk of developing advanced AMD when supplementing. [1] Long-term 10-year follow-up from the same trial cohort showed that adding lutein/zeaxanthin to the AREDS supplement formula reduced progression to advanced AMD by approximately 20% compared to those without it — and crucially, replacing beta-carotene (which increases lung cancer risk in former smokers) with lutein/zeaxanthin maintained protective benefit without that risk. [2]

Mediterranean Diet — More Than the Sum of Its Parts

The Mediterranean dietary pattern — rich in fish, olive oil, vegetables, legumes, whole grains, nuts, and fruit, with limited red meat and processed foods — is one of the most consistent dietary predictors of AMD risk across multiple independent cohorts.

In the EYE-RISK Consortium study pooling the Rotterdam Study (Netherlands) and Alienor Study (France), higher adherence to the Mediterranean diet was associated with a 41% reduced risk of developing advanced AMD over up to 21 years of follow-up, after adjusting for smoking, body mass index, education, and genetic susceptibility. [3] This is a large protective effect for a purely dietary observation.

The mechanisms are multiple:

• Anti-inflammatory omega-3 fatty acids from fish reduce complement-mediated inflammation that drives drusen formation
• Carotenoids from vegetables directly feed macular pigment
• Polyphenols from olive oil, nuts, and berries reduce retinal oxidative stress
• Low glycaemic load — high-glycaemic diets are independently associated with AMD risk, likely through oxidative byproducts of glucose metabolism in the retina

Practically, the most AMD-protective meal pattern involves eating fatty fish (salmon, sardines, mackerel) at least twice a week, making leafy greens a daily habit, using olive oil as the primary fat, and replacing refined grains and ultra-processed foods with legumes and whole grains. See our Mediterranean Diet page for a fuller overview.

Smoking — the Most Important Modifiable Risk

A systematic review of 17 studies confirmed that smokers have approximately 2–3 times the risk of developing AMD compared to non-smokers, and the risk is dose-dependent — meaning pack-years (the cumulative exposure) matter. [4] Among people who already have AMD, smoking accelerates progression significantly. The mechanism involves multiple pathways: nicotine and combustion products generate free radicals that deplete antioxidant enzymes in the RPE, thicken Bruch's membrane (the layer beneath the RPE), reduce choroidal blood flow, and directly stimulate the complement pathway implicated in AMD pathology.

Critically, the risk does not immediately normalise on cessation. Former smokers remain at elevated risk for years, though risk does gradually decline. For someone genetically predisposed to AMD (variants in CFH, ARMS2, and other complement genes substantially increase lifetime risk), continuing to smoke is particularly consequential — the interaction between genetic risk and smoking is multiplicative rather than additive.

Omega-3 Fatty Acids — Protective in Observational Data, Mixed in Trials

Multiple large prospective cohort studies show that people with high dietary intake of long-chain omega-3 fatty acids (EPA and DHA from fatty fish) have meaningfully lower rates of AMD onset and progression. The biology makes sense: DHA is highly concentrated in photoreceptor outer segments, and EPA reduces complement-mediated and COX-pathway inflammation in the RPE.

However, translating this to supplementation trials has proved more difficult. A Cochrane systematic review of omega-3 supplementation for AMD concluded that current trial evidence does not establish that supplements slow AMD progression, despite the strong epidemiological signal. [5] The AREDS2 trial, which tested 350 mg DHA + 650 mg EPA daily for 5 years, did not find a significant benefit for omega-3 supplements beyond the antioxidant formula. [1]

This apparent paradox — strong observational association, weak supplementation trial evidence — is common in nutrition research and likely reflects that: (1) dietary fish provides omega-3s in a matrix of other nutrients absent from supplements; (2) people who eat fish regularly also eat better overall; (3) supplements may be most beneficial earlier in the disease course than trial participants typically represent; or (4) dose and duration in trials may be insufficient.

The practical implication: prioritise fatty fish over fish oil capsules, and treat omega-3-rich foods as part of a broader AMD-protective dietary pattern rather than relying on supplements alone.

Physical Activity

A multicohort study pooling data from 14,630 adults across 7 population-based studies found that low-to-moderate physical activity was associated with significantly increased risk of developing early AMD compared to high physical activity levels. [6] The protective mechanisms likely involve improved choroidal blood flow, reduced systemic inflammation and oxidative stress, and metabolic benefits including lower BMI (obesity is an independent AMD risk factor through its effect on complement activity and oxidative stress).

Regular aerobic exercise — brisk walking, cycling, swimming — appears sufficient. Vigorous exercise is not required. The key is consistency rather than intensity.

UV Protection and Blue Light

While evidence for blue-light-blocking lenses is still being evaluated, ultraviolet (UV) radiation — particularly UVA and UVB — is established as damaging to the RPE and has been associated with increased drusen formation and AMD risk in outdoor workers and those with high cumulative sun exposure. Wearing UV-protective sunglasses (wraparound for full peripheral coverage) when outdoors, particularly during peak UV hours, is a low-risk, rational precaution especially for those with fair skin, light-coloured irises, or family history of AMD.

Supplement Summary — the AREDS2 Formula

For people who already have intermediate AMD or advanced AMD in one eye, the AREDS2 supplement formula has the strongest clinical evidence for slowing progression to advanced AMD. The formula contains: vitamin C (500 mg), vitamin E (400 IU as dl-alpha-tocopheryl acetate), zinc oxide (80 mg) with cupric oxide (2 mg), and lutein (10 mg) + zeaxanthin (2 mg). This is not a general-public supplement but a therapeutic dose for people at high risk of progression — discuss with an ophthalmologist who is monitoring your AMD status before starting.